{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-016301","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2023-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.307313+00:00","generated_at":"2026-06-10T02:34:39.467690+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Olema and Novartis expand Phase 1/2 combo study of palazestrant + ribociclib to ~60 patients","bullets":["Amendment adds ~30 patients to dose expansion, increasing study size to about 60 total.","Phase 1b dose escalation completed; Phase 2 expansion at 120 mg palazestrant + 600 mg ribociclib.","Expanded dataset may support regulatory path for a first-line pivotal trial in ER+ breast cancer.","Collaboration originally signed July 2020; amended in January 2022 and now expanded again.","Olema (OLMA) and Novartis (NVS) partner on this combination trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-016301","json":"https://secwatch.observer/filing/0001558370-23-016301.json","markdown":"https://secwatch.observer/filing/0001558370-23-016301.md","text":"https://secwatch.observer/filing/0001558370-23-016301.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023016301/0001558370-23-016301-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023016301/olma-20231009x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T02:34:39.467690+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e3af95c807b69214859293e8a84ed217dbb5e453","claim":"Olema Pharmaceuticals, Inc. amended Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply Agreement with Novartis Institutes for BioMedical Research, Inc. (effective 2023-10-09).","evidence_excerpt":"On October 9, 2023, Olema Pharmaceuticals, Inc. (the “Company”) entered into an Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply Agreement (the “Amendment”) with Novartis Institutes for BioMedical Research, Inc. (“Novartis”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023016301/0001558370-23-016301-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Novartis Institutes for BioMedical Research, Inc."},{"label":"Effective","value":"2023-10-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}